Zepbound News

Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds - Reuters

Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds Reuters

Opinion | The Great American GLP-1 Experiment - The New York Times

Opinion | The Great American GLP-1 Experiment The New York Times

Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it - NPR

Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it NPR

Exclusive: Walmart pushes beyond prescriptions in GLP-1 race - Axios

Exclusive: Walmart pushes beyond prescriptions in GLP-1 race Axios

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market - CNBC

FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market CNBC

A new weight-loss pill is here. Here's how Foundayo compares to Wegovy, Zepbound, and other GLP-1 rivals. - Business Insider

A new weight-loss pill is here. Here's how Foundayo compares to Wegovy, Zepbound, and other GLP-1 rivals. Business Insider

US weight-loss drugmakers slash prices in fight to win customers - BBC

US weight-loss drugmakers slash prices in fight to win customers BBC

When Weight-Loss Drugs Don’t Work - The New York Times

When Weight-Loss Drugs Don’t Work The New York Times

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial - CNBC

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial CNBC

Zepbound leads to greater weight loss — and muscle loss — than Wegovy: study - FirstWord Pharma

Zepbound leads to greater weight loss — and muscle loss — than Wegovy: study FirstWord Pharma

5 Pharmacist-Backed Tips for Using Zepbound Injections for Weight Loss - GoodRx

5 Pharmacist-Backed Tips for Using Zepbound Injections for Weight Loss GoodRx

She Lost 100 Pounds on Zepbound. Then Her Insurance Cut Her Off - Business Insider

She Lost 100 Pounds on Zepbound. Then Her Insurance Cut Her Off Business Insider

The new high dose of Wegovy costs less than Zepbound - MarketWatch

The new high dose of Wegovy costs less than Zepbound MarketWatch

Lilly’s obesity pill draws 1,390 US prescriptions in launch week - KFGO

Lilly’s obesity pill draws 1,390 US prescriptions in launch week KFGO

Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect - Eli Lilly and Company

Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect Eli Lilly and Company

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire - The Motley Fool

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire The Motley Fool

Louisiana Medicaid might add coverage for popular obesity treatment drugs - Louisiana Illuminator

Louisiana Medicaid might add coverage for popular obesity treatment drugs Louisiana Illuminator

GoodRx and Eli Lilly Partner to Expand Access to Foundayo and Zepbound KwikPen - Pharmaceutical Commerce

GoodRx and Eli Lilly Partner to Expand Access to Foundayo and Zepbound KwikPen Pharmaceutical Commerce

What I Wish I Knew About the Importance of Support When Starting a GLP-1 Medication - health.com

What I Wish I Knew About the Importance of Support When Starting a GLP-1 Medication health.com

Pricing and availability of Novo, Lilly's weight-loss drugs - Reuters

Pricing and availability of Novo, Lilly's weight-loss drugs Reuters

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly and Company

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen Eli Lilly and Company

Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook - Yahoo Finance

Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook Yahoo Finance

Eli Lilly's Weight Loss Portfolio: Zepbound and Retatrutide Strategy - News and Statistics - IndexBox

Eli Lilly's Weight Loss Portfolio: Zepbound and Retatrutide Strategy - News and Statistics IndexBox

The FDA approves a new obesity pill, giving patients another option - NPR

The FDA approves a new obesity pill, giving patients another option NPR

Multi-Dose KwikPen Now Available for Zepbound Administration - Gastroenterology Advisor

Multi-Dose KwikPen Now Available for Zepbound Administration Gastroenterology Advisor

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen - CNBC

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen CNBC

Jennifer O'Connell: Are GLP-1s like Ozempic and Mounjaro the cure for everything? - The Irish Times

Jennifer O'Connell: Are GLP-1s like Ozempic and Mounjaro the cure for everything? The Irish Times

Zepbound Blindness Lawsuit [2026 Update] - robertkinglawfirm.com

Zepbound Blindness Lawsuit [2026 Update] robertkinglawfirm.com

Ads for GLP-1 drugs are flooding the internet – here’s how to know if it’s safe to buy them online - The Conversation

Ads for GLP-1 drugs are flooding the internet – here’s how to know if it’s safe to buy them online The Conversation

Publix Pharmacy provides access to savings on GLP-1 Zepbound multi-dose KwikPen - Publix

Publix Pharmacy provides access to savings on GLP-1 Zepbound multi-dose KwikPen Publix

The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound - Scientific American

The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound Scientific American

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight - Eli Lilly and Company

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight Eli Lilly and Company